Baidu
map

Eur Ann Allergy Clin Immunol :过敏症对患有注意力缺陷多动障碍儿童的影响

2018-08-06 AlexYang MedSci原创

注意力缺陷多动障碍(ADHD)在全世界范围内常见,并对那些受影响的患者造成了严重的问题。ADHD从属于过敏障碍或者过敏障碍医药治疗。ADHD和过敏均依赖于复杂的环境和遗传互作,并且它们还满足超敏反应标准。最近,有研究人员在ADHD儿童中检测了过敏的占比,包括常见的过敏障碍和过敏原,以及过敏对ADHD症状和严重度的影响。研究包括了100名患有ADHD的儿童,并进行精神病评估,从而了解ADHD类型和严

注意力缺陷多动障碍(ADHD)在全世界范围内常见,并对那些受影响的患者造成了严重的问题。ADHD从属于过敏障碍或者过敏障碍医药治疗。ADHD和过敏均依赖于复杂的环境和遗传互作,并且它们还满足超敏反应标准。最近,有研究人员在ADHD儿童中检测了过敏的占比,包括常见的过敏障碍和过敏原,以及过敏对ADHD症状和严重度的影响。

研究包括了100名患有ADHD的儿童,并进行精神病评估,从而了解ADHD类型和严重度、过敏历史、对常见环境过敏原的皮刺试验测试、血清lgE水平和开放食物挑战。研究排除了共病神经精神障碍,低于平均智商(IQ)和慢性疾病的患者。对照包括了60健康儿童,并与患者儿童进行相关比较。研究发现,35名ADHD儿童(35%)患有过敏症。大多数案例具有过敏性鼻炎和支气管哮喘(25%)组合病症。常见的过敏原味干草粉(43%)和不同种类的花粉(37.5%)。另外,在过敏症共存、ADHD类型、早发和症状严重度之间具有统计学显著意义。

最后,研究人员指出,患有ADHD的儿童过敏性疾病流行度增加。在ADHD患者中评估过敏症是必须的,从而减少相关负担。

原始出处:

Abd El-Hamid ZB, Refaat MM, El-Shahawy HH et al. Impact of allergy on children with attention deficit hyperactivity disorder. Eur Ann Allergy Clin Immunol. 1 Aug 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1705104, encodeId=79e21e05104e1, content=<a href='/topic/show?id=6fdf650130a' target=_blank style='color:#2F92EE;'>#注意力缺陷多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65013, encryptionId=6fdf650130a, topicName=注意力缺陷多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Sep 10 00:42:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968844, encodeId=83a9196884446, content=<a href='/topic/show?id=01be430e1c3' target=_blank style='color:#2F92EE;'>#多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43071, encryptionId=01be430e1c3, topicName=多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Oct 04 22:42:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329139, encodeId=e9841329139df, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515702, encodeId=d7aa1515e02c5, content=<a href='/topic/show?id=cd636500e2e' target=_blank style='color:#2F92EE;'>#注意力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65007, encryptionId=cd636500e2e, topicName=注意力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=096e10855142, createdName=12498c24m72暂无昵称, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516456, encodeId=842c1516456d9, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1705104, encodeId=79e21e05104e1, content=<a href='/topic/show?id=6fdf650130a' target=_blank style='color:#2F92EE;'>#注意力缺陷多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65013, encryptionId=6fdf650130a, topicName=注意力缺陷多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Sep 10 00:42:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968844, encodeId=83a9196884446, content=<a href='/topic/show?id=01be430e1c3' target=_blank style='color:#2F92EE;'>#多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43071, encryptionId=01be430e1c3, topicName=多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Oct 04 22:42:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329139, encodeId=e9841329139df, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515702, encodeId=d7aa1515e02c5, content=<a href='/topic/show?id=cd636500e2e' target=_blank style='color:#2F92EE;'>#注意力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65007, encryptionId=cd636500e2e, topicName=注意力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=096e10855142, createdName=12498c24m72暂无昵称, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516456, encodeId=842c1516456d9, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1705104, encodeId=79e21e05104e1, content=<a href='/topic/show?id=6fdf650130a' target=_blank style='color:#2F92EE;'>#注意力缺陷多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65013, encryptionId=6fdf650130a, topicName=注意力缺陷多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Sep 10 00:42:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968844, encodeId=83a9196884446, content=<a href='/topic/show?id=01be430e1c3' target=_blank style='color:#2F92EE;'>#多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43071, encryptionId=01be430e1c3, topicName=多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Oct 04 22:42:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329139, encodeId=e9841329139df, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515702, encodeId=d7aa1515e02c5, content=<a href='/topic/show?id=cd636500e2e' target=_blank style='color:#2F92EE;'>#注意力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65007, encryptionId=cd636500e2e, topicName=注意力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=096e10855142, createdName=12498c24m72暂无昵称, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516456, encodeId=842c1516456d9, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
    2018-08-08 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=1705104, encodeId=79e21e05104e1, content=<a href='/topic/show?id=6fdf650130a' target=_blank style='color:#2F92EE;'>#注意力缺陷多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65013, encryptionId=6fdf650130a, topicName=注意力缺陷多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Sep 10 00:42:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968844, encodeId=83a9196884446, content=<a href='/topic/show?id=01be430e1c3' target=_blank style='color:#2F92EE;'>#多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43071, encryptionId=01be430e1c3, topicName=多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Oct 04 22:42:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329139, encodeId=e9841329139df, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515702, encodeId=d7aa1515e02c5, content=<a href='/topic/show?id=cd636500e2e' target=_blank style='color:#2F92EE;'>#注意力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65007, encryptionId=cd636500e2e, topicName=注意力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=096e10855142, createdName=12498c24m72暂无昵称, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516456, encodeId=842c1516456d9, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1705104, encodeId=79e21e05104e1, content=<a href='/topic/show?id=6fdf650130a' target=_blank style='color:#2F92EE;'>#注意力缺陷多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65013, encryptionId=6fdf650130a, topicName=注意力缺陷多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Sep 10 00:42:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968844, encodeId=83a9196884446, content=<a href='/topic/show?id=01be430e1c3' target=_blank style='color:#2F92EE;'>#多动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43071, encryptionId=01be430e1c3, topicName=多动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Oct 04 22:42:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329139, encodeId=e9841329139df, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515702, encodeId=d7aa1515e02c5, content=<a href='/topic/show?id=cd636500e2e' target=_blank style='color:#2F92EE;'>#注意力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65007, encryptionId=cd636500e2e, topicName=注意力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=096e10855142, createdName=12498c24m72暂无昵称, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516456, encodeId=842c1516456d9, content=<a href='/topic/show?id=0c06940668a' target=_blank style='color:#2F92EE;'>#过敏症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94066, encryptionId=0c06940668a, topicName=过敏症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=def310968681, createdName=ms1948154235210413, createdTime=Wed Aug 08 11:42:00 CST 2018, time=2018-08-08, status=1, ipAttribution=)]

相关资讯

J Asthma:气流阻塞抗性儿童临床特性分析

最近,有研究人员鉴定了患有气流受限且对支气管扩张剂(BD)治疗具有抗性儿童的相关特性。研究鉴定了582名儿童。平均年龄为13岁(IQR: 11, 16),其中60%为男性;62%为白种人,28%为非裔美国人;19%为肥胖;32%为早产儿和21%的接触二手烟。肺部诊断包括了哮喘(93%),之前严重的肺炎(28%)和支气管扩张(5%)。65%报道具有过敏性鼻炎,11%患有慢性鼻窦炎。没有哮喘历史的参与

Sci Rep:注意力缺陷多动症与过敏症状和低水平的血红蛋白和血清素相关

最近,有研究人员调查了是否常见的并发症或者生化因子,比如过敏性疾病、贫血、炎症和神经传导物质,单独或者组合地与注意力缺陷多动症障碍(ADHD)风险的增加相关。研究募集了216名诊断为ADHD的儿童,包括了216名在年龄、性别、身高、体重和年纪匹配的对照,他们均来自台北市的小学。研究人员利用哮喘和过敏国际调查问卷的儿童调查问卷测量了过敏症状,搜集了空腹静脉血来分析全血细胞计数、白细胞分类计数、免疫球

Med Princ Pract:关于儿童哮喘、过敏性鼻炎和过敏性皮肤炎的AAA风险因素量表研究

为了获得过敏性疾病风险因素量表评分,从而可以用来在3-17岁儿童中进行进行哮喘、过敏性鼻炎和过敏性皮肤炎风险评估,最近,有研究人员进行了相关研究。研究是一个案例-对照研究,并在2015年12月和2016年4月之间进行,包括了1274名儿童。过敏性疾病风险因素量表的获得结合了环境、孕期毒性物质的接触、母乳喂养和父母过敏性疾病历史。研究发现,在地毯上玩耍、男性、儿童呼吸道问题或者2岁之前湿疹历史以及湿

Rev Soc Bras Med Trop:在HTLV-1感染患者中,特应性反应和神经表现关系研究

人类T淋巴细胞病毒类型1(HTLV-1)能够诱导过度的Th1响应,然而特应性反应与加剧的Th2响应相关。最近,有研究人员进行了一个代表性的研究,研究比较了HTLV-1携带者和HAM/TSP患者特应性反应的流行度,同时也比较了自发性的细胞因子在HTLV-1感染者个体中的产生情况。另外,一个回顾性的群体研究评估了特应性反应和非特应性反应携带者中,神经表现的发育情况。研究发现,具有高IFN-γ产生的特应

变应性鼻炎都可以免疫治疗吗?

问:是不是只要是变应性鼻炎就可以免疫治疗呢?答:不是的。过敏性鼻炎,医生也称变应性鼻炎(简称AR),咱老百姓就简称“鼻炎”。是特应性个体接触变应原后由IgE介导的鼻黏膜炎症反应性疾病。简单点来说就是容易过敏的人,接触了导致你过敏的东西后,引起了鼻子的不舒服的反应。这些不舒服的反应主要包括反复喷嚏、流清水样的鼻涕、鼻塞和鼻痒,有时候有眼痒、结膜充血和/或流泪。最新的研究表明过敏性鼻炎在我国大陆地区

Allergol Immunopathol (Madr):环境接触和CD4+CD25+调控T细胞相关性研究

之前的研究认为,农业区域的年轻患者由于对内毒素的高度接触,起到了免受过敏和哮喘的作用。最近,有研究人员在乡村和农场地区比较了对屋尘螨(HDM)过敏CD4+CD25+调控T细胞和叉头状转录因子Foxp3表达。研究是一个前瞻性的分析,包括了35名儿童,其中19名居住在农村区域,16名居住在乡村区域,年龄在8到16岁。他们均患有过敏性鼻炎(对屋尘螨过敏)和新诊断的哮喘。研究人员还利用流式细胞仪,使用荧光

Baidu
map
Baidu
map
Baidu
map